Morphological changes in the liver of experimental animals with combined introduction of adribastin and FOXO4-DRI
https://doi.org/10.34680/2076-8052.2023.2(131).216-222
Abstract
Doxorubicin is actively used in scientific practice not only as a chemotherapeutic drug, but also as a senescence inducer due to its mechanism of action, namely, the blocking of mitosis, the development of mitochondrial dysfunction and DNA intercalation, which is most pronounced in labile cell populations. The senescent phenotype is currently considered as one of the possible options for the induction of prooncogenes, failure of repair processes and local inflammatory response. The combined use of senolytics together with chemotherapy drugs has been used for a long time (quercetin and dasatinib), however, the combination of peptide-based senolytics (FOXO4-DRI) with doxorubicin seems to be one of the most promising. This article discusses the combined use of FOXO4-DRI and doxorubicin in female and male mice in the early stages. As a result, microscopic examination showed a moderate protective effect of the senolytic peptide on the liver cell population, a decrease in the degree of leukocyte infiltration, and a decrease in the degree of fatty infiltration. There was a significant difference in responses between animals of different sexes.
About the Authors
A. A. Yakovlev
Izhevsk State Medical Academy of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Yakovlev A. A.,
Izhevsk.
Yu. G. Vasiliev
Udmurt State Agricultural University
Russian Federation
Russian Federation
Vasiliev Yu. G.,
Izhevsk.
G. V. Shumikhina
Izhevsk State Medical Academy of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Shumikhina G. V.,
Izhevsk.
D. S. Berestov
Udmurt State Agricultural University
Russian Federation
Russian Federation
Berestov D. S.,
Izhevsk.
References
1. Harrington K. L., Lewanski C. R., Stewart J. S. Liposomes as vehicles for targeted therapy of cancer. Part.2: Clinical development // Clinical oncology. 2000. 12(1). 16-24. DOI: 10.1053/clon.2000.9105
2. Ewer M. S., Benjamin R. S. Cardiotoxicity of chemotherapeutic Drugs // The Chemotherapy source book. Ed. M. C. Perry. New York, 1997. P. 458-468.
3. Olson R. D., Mushlin P. S., Brenner D. E., Fleischer S., Cusack B. J., Chang B. K., Boucek Jr. R. J. Doxorubicin cardiotoxicity may be due to its metabolite, doxorubicinol // Proceedings of the National Academy of Sciences of the United States of America. 1998. 85(10). 3585-3589. DOI: 10.1073/pnas.85.10.3585
4. Bazikov I. A., Beyer E. V., Lukinova V. V., Maltsev A. N. Sravnitel'naya ocenka ostroj toksichnosti doksorubicina i ego niosomal'noj formy [Comparative evaluation of the acute toxicity of doxorubicin and its niosomal form] // Medical News of the North Caucasus. 2015. 10(4). 403-406. DOI: 10.14300/mnnc.2015.10098
5. Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv. Ch. 1 [Guidelines for conducting preclinical studies of drugs. Part 1]. Ed. A.N. Mironov. Moscow, Grif i K Publ., 2012. 944 p. Available at: https://rsmu.ru/fileadmin/templates/DOC/Zakon_RF/Mironov_Rukovodstvo_po_provedeniju_doklinicheskikh_issledovanii_lekarstvennykh_sredstv.pdf (Accessed: 08.11.2022).
6. Pravila laboratornoj praktiki: Prikaz Ministerstva zdravoohraneniya Rossijskoj Federacii № 708 n ot 23.08.2010 [Rules of laboratory practice: Order of the Ministry of Health of the Russian Federation No. 708 n dated 08/23/2010]. Available at: https://normativ.kontur.ru/document?moduleId=1&documentId=165691 (Accessed: 16.12.2022).
7. Pravila provedeniya rabot s ispol'zovaniem eksperimental'nyh zhivotnyh: Prikaz MZ SSSR № 755 ot 12.08.1977 [Rules for carrying out work using experimental animals: Order of the Ministry of Health of the USSR No. 755 of 12.08.1977]. Available at: https://primatologia.ru/images/NII/GLP/3_2_prikaz_minzdrawa_o_merah_zhiwotnyh.pdf (Accessed: 15.12.2022).
8. European Convention for the Protection of Vertebrate Animals Used for Experimental and other Scientific Purposes (ETS 123). Strasbourg, 1986. Available at: http://www.worldlii.org/int/other/treaties/COETSER/1986/1.html (Accessed: 30.11.2022).
9. Vasiliev Yu. G., Shumikhina G. V., Berestov D. S., Korepanov Yu. B. Strukturnyye osobennosti selezenki myshey v razlichnykh funktsional'nykh sostoyaniyakh[Structural features of the spleen of mice in various functional states] // Proceedings of the Izhevsk State Medical Academy: a collection of scientific articles, vol. 59. Izhevsk, Izhevsk State Medical Academy, 2021. P. 21-23.
10. Vasiliev Yu. G., Vasiliev R. O., Berestov D. S. Morfologiya selezenki myshej v kontrole i v hode immunosupressii [Morphology of the spleen of mice in control and during immunosuppression] // Technological trends in sustainable functioning and development of the agro-industrial complex: materials of the International scientific and practical conference dedicated to the year of science and technology in Russia, Izhevsk, February 24–26, 2021. Izhevsk, Izhevsk State Agricultural Academy, 2021. P. 91-95.
11. Yakovlev A. A., Vasiliev Yu. G., Shumikhina G. V., Berestov D. S. Morfologicheskiye izmeneniya v pecheni na vvedeniye doksorubitsina u eksperimental'nykh zhivotnykh [Morphological changes in the liver on the introduction of doxorubicin in experimental animals] // Vestnik NovSU. 2022. 2(127). 51-54. DOI: 10.34680/2076-8052.2022.2(127).51-54
Review
For citations:
Yakovlev A.A., Vasiliev Yu.G., Shumikhina G.V., Berestov D.S. Morphological changes in the liver of experimental animals with combined introduction of adribastin and FOXO4-DRI. Title in english. 2023;(2(131)):216-222. (In Russ.) https://doi.org/10.34680/2076-8052.2023.2(131).216-222
Views:
56
Email this article 